| Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma. | |
| | |
MedLine Citation:
|
PMID: 23225462 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
BACKGROUND: Although high-dose chemotherapy (HDC) represents the standard of treatment for high-risk neuroblastoma (NBL), the most effective conditioning regimen still remains to be identified. PATIENTS AND METHODS: Forty-one high-risk NBL entered into local protocol based on induction chemotherapy, surgery and HDC with either etoposide/thiotepa/cyclophophamide (ETC) or i.v. busulfan and L-PAM (Bu/L-PAM). RESULTS: Thirty-seven patients underwent HDC; 29 with ETC and 8 with Bu/L-PAM. No toxic deaths were recorded. The 5-year progression-free survival (PFS) of patients given ETC was 21% (95% confidence interval CI (9-36%), while PFS for patients given Bu/L-PAM was 88% (95% CI=39-98%) (p<0.05). In multivariate analysis, treatment with the ETC regimen predicted progression/recurrence with a hazard ratio (HR) of 16.8 (p<0.05), as well as MYCN amplification which had an HR of 4.4 (p<0.05). CONCLUSION: Although the number of studied cases is limited, our data suggest that in high-risk NBL the combination of Bu/L-PAM is superior to the ETC regimen. |
| | |
Authors:
|
Maria Antonietta DE Ioris; Benedetta Contoli; Alessandro Jenkner; Maria Debora DE Pasquale; Annalisa Serra; Luigi DE Sio; Rosanna Pessolano; Maria Carmen Garganese; Alessandro Crocoli; Teresa Corneli; Renata Boldrini; Aurora Castellano |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Anticancer research Volume: 32 ISSN: 1791-7530 ISO Abbreviation: Anticancer Res. Publication Date: 2012 Dec |
Date Detail:
|
Created Date: 2012-12-10 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8102988 Medline TA: Anticancer Res Country: Greece |
Other Details:
|
Languages: eng Pagination: 5527-33 Citation Subset: IM |
Affiliation:
|
Hematology/Oncology Department, Bambino Gesù Children Hospital, Rome, Italy. deioris@opbg.net. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colore...
Next Document: Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of ...